Omeros Reports Q1 Net Income of $56.1M, Launches YARTEMLEA for TA-TMA
OMER•Omeros reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, driven by initial commercial sales of YARTEMLEA. The therapy, approved for hematopoietic stem cell transplant-associated thrombotic microangiopathy, began generating revenue as rollout commenced in the quarter.
1. Q1 Financial Performance
Omeros recorded net income of $56.1 million, or $0.78 per share, in the first quarter of 2026, marking its first profitable quarter following extensive R&D investment. The result reflects both improved operational efficiency and the impact of new product commercialization.
2. Commercial Launch of YARTEMLEA
The company commenced commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, in early Q1 2026. Revenue from initial orders underscores the therapy’s market entry and sets the stage for broader rollout in transplant centers.
